Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates

Key Points

• Q1 earnings: Acrivon reported EPS of ($0.49), which matched the consensus estimate, and the stock was down about 1.1% as shares opened at $1.68 (market cap ~$53.1M).
• Insider confidence: CEO Peter Blume-Jensen purchased 49,000 shares at $1.68, raising his stake to 2,095,771 shares (a 2.39% increase); company insiders now own 11.90% of the stock.
• Analyst mix: Ratings are mixed but tilted positive—MarketBeat shows a "Moderate Buy" consensus with an average price target of $11.67, while individual targets and ratings range from sells to a $19 price goal.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, hitting the consensus estimate of ($0.49), FiscalAI reports.

Acrivon Therapeutics Stock Down 1.1%

Shares of NASDAQ:ACRV opened at $1.68 on Friday. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $5.65. The business has a 50 day moving average of $1.71 and a 200-day moving average of $1.94. The stock has a market cap of $53.08 million, a PE ratio of -0.78 and a beta of 1.79.

Insiders Place Their Bets

In other news, CEO Peter Blume-Jensen purchased 49,000 shares of Acrivon Therapeutics stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average cost of $1.68 per share, for a total transaction of $82,320.00. Following the purchase, the chief executive officer directly owned 2,095,771 shares of the company's stock, valued at $3,520,895.28. This trade represents a 2.39% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders purchased 67,832 shares of company stock worth $114,534. Company insiders own 11.90% of the company's stock.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics in the first quarter valued at about $72,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics during the second quarter worth about $126,000. Jane Street Group LLC bought a new position in Acrivon Therapeutics during the second quarter worth about $371,000. UBS Group AG boosted its holdings in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company's stock valued at $1,237,000 after purchasing an additional 682,763 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock valued at $578,000 after purchasing an additional 138,033 shares during the period. Institutional investors and hedge funds own 71.62% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ACRV shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Jefferies Financial Group restated a "buy" rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Acrivon Therapeutics in a research report on Tuesday, November 25th. Wall Street Zen lowered Acrivon Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, March 1st. Finally, Piper Sandler raised their price target on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an "overweight" rating in a report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $11.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.